August 1, 2025The International Journal of NeuropsychopharmacologyOpen Access

Expanding Access to Ketamine Through Reformulation

View Full Paper

Ask AI

Bookmark

Extended-release ketamine tablets showed acute effectiveness in 73% of patients with treatment resistant depression.
The 180 mg tablet group achieved a mean MADRS score reduction of −6.1 compared to placebo, indicating significant improvement.
Patients tolerated the treatment well, with minimal sedation and dissociation reported during home dosing.
Results indicate that expanding access to at-home ketamine treatment could benefit more patients with treatment resistant depression.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase 2 trial shows improved tolerability and efficacy of extended-release ketamine in patients with treatment resistant depression, suggesting potential for home dosing.

Cite This Study

Paul Glue (2025) studied this question.

synapsesocial.com/papers/68af2ee5cf1dd9ea359e67c4 https://doi.org/10.1093/ijnp/pyaf052.397

View Full Paper

Ask AI

Bookmark

Implication

Phase 2 trial shows improved tolerability and efficacy of extended-release ketamine in patients with treatment resistant depression, suggesting potential for home dosing.

Expanding Access to Ketamine Through Reformulation

Key Points

Discussion

Implication

Cite This Study

Expanding Access to Ketamine Through Reformulation

Key Points

Discussion

Implication

Cite This Study

Keep reading

Keep reading